Alice Jiang, MD
Ophthalmology · Indianapolis, INNPI 1255969119
Payments from drug & device makers
Across 20 payments — averaging $53.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$226
- Alcon$209
- Carl Zeiss Meditec USA, Inc.$160
- Sight Sciences, Inc.$120
- Regeneron Healthcare Solutions, Inc.$116
- Dompe US, Inc.$65
- plus $169 from 7 others
What the payments were for
- Food & beverage$1,064100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 5 | $226 |
| Alcon | 3 | $209 |
| Carl Zeiss Meditec USA, Inc. | 1 | $160 |
| Sight Sciences, Inc. | 1 | $120 |
| Regeneron Healthcare Solutions, Inc. | 1 | $116 |
| Dompe US, Inc. | 2 | $65 |
| Nova Eye, Inc. | 1 | $55 |
| AbbVie | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $23 |
| Thea Pharma Inc. | 1 | $20 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Rxsight Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMERA 700$160
- Clareon$144
- XDEMVY$120
- OMNI(R) SURGICAL SYSTEM (US)$120
- EYLEA$116
How this compares
$1,064 in reported general payments places this provider in the 45th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 63 | $2,864 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 13 | $1,322 |
| Brimonidine Tartrate | 18 | $1,032 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $697 |
| Timolol Maleate | 15 | $684 |
| MoxifloxacinMoxifloxacin Hcl | 42 | $530 |
| Latanoprost | 49 | $439 |
| Ketorolac Tromethamine | 13 | $149 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$765K
- Francis PriceIndianapolis$500K
- Blair BoehmerIndianapolis$128K
- John LindIndianapolis$125K
- William WhitsonIndianapolis$98K
- Janet HummerIndianapolis$96K
- Shaohui LiuIndianapolis$92K
- Darrell WudunnIndianapolis$67K
- Robert DeitchIndianapolis$27K
- Michael OrrIndianapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.